News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Longest survival follow-up ever reported for immunotherapy treatment in this setting
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Subscribe To Our Newsletter & Stay Updated
